RT Journal Article
SR Electronic
T1 Systematic evaluation of SARS-CoV-2 spike protein derived peptides for diagnosis of COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.01.20186387
DO 10.1101/2020.09.01.20186387
A1 Li, Yang
A1 Lai, Dan-yun
A1 Lei, Qing
A1 Xu, Zhao-wei
A1 Hou, Hongyan
A1 Chen, Lingyun
A1 Wu, Jiaoxiang
A1 Ren, Yan
A1 Ma, Ming-liang
A1 Zhang, Bo
A1 Chen, Hong
A1 Yu, Caizheng
A1 Xue, Jun-biao
A1 Zheng, Yun-xiao
A1 Wang, Xue-ning
A1 Jiang, He-wei
A1 Zhang, Hai-nan
A1 Qi, Huan
A1 Guo, Shu-juan
A1 Zhang, Yandi
A1 Lin, Xiaosong
A1 Yao, Zongjie
A1 Pang, Pengfei
A1 Shi, Dawei
A1 Wang, Wei
A1 Yang, Xiao
A1 Zhou, Jie
A1 Sheng, Huiming
A1 Sun, Ziyong
A1 Shan, Hong
A1 Wang, Feng
A1 Fan, Xionglin
A1 Tao, Sheng-ce
YR 2020
UL http://medrxiv.org/content/early/2020/09/03/2020.09.01.20186387.abstract
AB Serological test plays an essential role in monitoring and combating COVID-19 pandemic. Recombinant spike protein (S protein), especially S1 protein is one of the major reagents for serological tests. However, the high cost in production of S protein, and the possible cross-reactivity with other human coronaviruses poses unneglectable challenges. Taking advantage of a peptide microarray of full spike protein coverage, we analyzed 2,434 sera from 858 COVID-19 patients, sera from 63 asymptomatic patients and 610 controls collected from multiple clinical centers. Based on the results of the peptide microarray, we identified several S protein derived 12-mer peptides that have high diagnosis performance. Particularly, for monitoring IgG response, one peptide (aa 1148-1159 or S2-78) has a comparable sensitivity (95.5%, 95% CI 93.7-96.9%) and specificity (96.7%, 95% CI 94.8-98.0%) to that of S1 protein for detection of both COVID-19 patients and asymptomatic infections. Furthermore, the performance of S2-78 IgG for diagnosis was successfully validated by ELISA with an independent sample cohort. By combining S2-78/ S1 with other peptides, a two-step strategy was proposed to ensure both the sensitivity and specificity of S protein based serological assay. The peptide/s identified in this study could be applied independently or in combination with S1 protein for accurate, affordable, and accessible COVID-19 diagnosis.One Sentence Summary Eight S protein-derived peptides, particularly S2-78 (aa 1148-1159), are of high performance for diagnosis of COVID-19 as well as discrimination of other coronaviruses.Competing Interest StatementFour relevant patents which have been applied in China (application number: 202010413901.9, 202010415057.3, 202010415053.5 and 202010413911.2) are filed by Shanghai Jiao Tong University. S-C.T., Y.L., D-Y. L, H-W.J., H-N.Z. and H.Q. are relevant to these patents. Other authors declare no conflicts of interest.Funding StatementThis work was partially supported by National Key Research and Development Program of China Grant (No. 2016YFA0500600), Science and Technology Commission of Shanghai Municipality (No. 19441911900), Interdisciplinary Program of Shanghai Jiao Tong University (No. YG2020YQ10), National Natural Science Foundation of China (No. 31900112, 21907065, 31970130 and 31670831).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethical Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (ITJ-C20200128), Institutional Ethics Review Committee of Foshan Fourth Hospital, Foshan, China (202005) and the Ethical Committee of The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China (K14-2).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe peptide microarray data generated in this study has been deposited to Protein Microarray Database (http://www.proteinmicroarray.cn) under the accession number PMDE242 and PMDE244 Additional data related to this study may be requested from the authors. http://www.proteinmicroarray.cn